WO1998055607A3 - Tumor targeted vector - Google Patents

Tumor targeted vector Download PDF

Info

Publication number
WO1998055607A3
WO1998055607A3 PCT/GB1998/001627 GB9801627W WO9855607A3 WO 1998055607 A3 WO1998055607 A3 WO 1998055607A3 GB 9801627 W GB9801627 W GB 9801627W WO 9855607 A3 WO9855607 A3 WO 9855607A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor targeted
targeted vector
vector
noi
poi
Prior art date
Application number
PCT/GB1998/001627
Other languages
French (fr)
Other versions
WO1998055607A2 (en
Inventor
Susan Mary Kingsman
Christopher Robert Bebbington
Fiona Margaret Ellard
Miles William Carroll
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Susan Mary Kingsman
Christopher Robert Bebbington
Fiona Margaret Ellard
Miles William Carroll
Kevin Alan Myers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998055607(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9711579.4A external-priority patent/GB9711579D0/en
Priority claimed from GBGB9713150.2A external-priority patent/GB9713150D0/en
Priority claimed from GBGB9714230.1A external-priority patent/GB9714230D0/en
Priority to AT98925827T priority Critical patent/ATE444358T1/en
Priority to IL13259698A priority patent/IL132596A0/en
Priority to JP50185899A priority patent/JP2002507117A/en
Priority to US09/445,375 priority patent/US6852703B1/en
Priority to NZ500633A priority patent/NZ500633A/en
Priority to DK98925827.2T priority patent/DK1012259T3/en
Priority to EP98925827A priority patent/EP1012259B1/en
Priority to CA002292760A priority patent/CA2292760A1/en
Application filed by Oxford Biomedica Ltd, Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers filed Critical Oxford Biomedica Ltd
Priority to DE69841204T priority patent/DE69841204D1/en
Priority to AU77801/98A priority patent/AU747602B2/en
Priority to KR19997011207A priority patent/KR20010013219A/en
Publication of WO1998055607A2 publication Critical patent/WO1998055607A2/en
Publication of WO1998055607A3 publication Critical patent/WO1998055607A3/en
Priority to NO995901A priority patent/NO995901L/en
Priority to US10/104,522 priority patent/US7531648B2/en
Priority to US11/380,188 priority patent/US7718627B2/en
Priority to US11/834,649 priority patent/US20080175819A1/en
Priority to US12/186,839 priority patent/US20090017532A1/en
Priority to US12/714,264 priority patent/US8084249B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

A vector comprising a nucleotide sequence of interest ('NOI') encoding a product of interest ('POI') is described. The NOI and/or the POI is capable of recognising a tumour, such that in use the vector is capable of delivering the NOI and/or the POI to the tumour.
PCT/GB1998/001627 1997-06-04 1998-06-04 Tumor targeted vector WO1998055607A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
KR19997011207A KR20010013219A (en) 1997-06-04 1998-06-04 Vector
AU77801/98A AU747602B2 (en) 1997-06-04 1998-06-04 Vector
DE69841204T DE69841204D1 (en) 1997-06-04 1998-06-04 Tumor targeted vector
AT98925827T ATE444358T1 (en) 1997-06-04 1998-06-04 TUMOR TARGETED VECTOR
IL13259698A IL132596A0 (en) 1997-06-04 1998-06-04 Vector
JP50185899A JP2002507117A (en) 1997-06-04 1998-06-04 vector
US09/445,375 US6852703B1 (en) 1997-06-04 1998-06-04 Tumor targeted vector
NZ500633A NZ500633A (en) 1997-06-04 1998-06-04 Vector
DK98925827.2T DK1012259T3 (en) 1997-06-04 1998-06-04 Tumor-directed vector
EP98925827A EP1012259B1 (en) 1997-06-04 1998-06-04 Tumor targeted vector
CA002292760A CA2292760A1 (en) 1997-06-04 1998-06-04 Vector
NO995901A NO995901L (en) 1997-06-04 1999-12-02 Vector
US10/104,522 US7531648B2 (en) 1997-06-04 2002-03-22 Vector encoding an antibody that binds 5T4 antigen
US11/380,188 US7718627B2 (en) 1997-06-04 2006-04-25 Vector
US11/834,649 US20080175819A1 (en) 1997-06-04 2007-08-06 Vector system
US12/186,839 US20090017532A1 (en) 1997-06-04 2008-08-06 Vector
US12/714,264 US8084249B2 (en) 1997-06-04 2010-02-26 Vector

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9711579.4 1997-06-04
GBGB9711579.4A GB9711579D0 (en) 1997-06-04 1997-06-04 Therapeutic genes
GB9713150.2 1997-06-20
GBGB9713150.2A GB9713150D0 (en) 1997-06-20 1997-06-20 Fusion proteins
GBGB9714230.1A GB9714230D0 (en) 1997-07-04 1997-07-04 Therapeutic genes
GB9714230.1 1997-07-04

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US09/445,375 A-371-Of-International US6852703B1 (en) 1997-06-04 1998-06-04 Tumor targeted vector
US09445375 A-371-Of-International 1998-06-04
PCT/GB2000/004317 Continuation-In-Part WO2001036486A2 (en) 1997-06-04 2000-11-13 Scfv antibodies against disease associated molecules
US10/104,522 Division US7531648B2 (en) 1997-06-04 2002-03-22 Vector encoding an antibody that binds 5T4 antigen
US10/787,881 Division US20050032216A1 (en) 1997-06-04 2004-02-25 Vector

Publications (2)

Publication Number Publication Date
WO1998055607A2 WO1998055607A2 (en) 1998-12-10
WO1998055607A3 true WO1998055607A3 (en) 1999-03-04

Family

ID=27268875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001627 WO1998055607A2 (en) 1997-06-04 1998-06-04 Tumor targeted vector

Country Status (16)

Country Link
US (6) US6852703B1 (en)
EP (2) EP1717248A1 (en)
JP (3) JP2002507117A (en)
CN (1) CN1224712C (en)
AT (1) ATE444358T1 (en)
AU (1) AU747602B2 (en)
CA (1) CA2292760A1 (en)
CY (1) CY1109686T1 (en)
DE (1) DE69841204D1 (en)
DK (1) DK1012259T3 (en)
ES (1) ES2332435T3 (en)
IL (1) IL132596A0 (en)
NO (1) NO995901L (en)
NZ (1) NZ500633A (en)
PT (1) PT1012259E (en)
WO (1) WO1998055607A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ES2332435T3 (en) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited VECTOR DIRECTED TO TUMORS.
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
ATE411342T1 (en) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd SCFV ANTIBODIES AGAINST DISEASE-ASSOCIATED MOLECULES
JP2003515323A (en) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド Body
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7629153B2 (en) * 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
KR20040054699A (en) * 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 Methods and compositions relating to restricted expression lentiviral vectors and their applications
DE60237704D1 (en) * 2001-10-16 2010-10-28 Government Of The Us Secretary NEUTRALIZING ANTIBODIES TO HIV WITH A WIDE CROSS-REACTION SELECTED BY ENV-CD4-CO RECEPTOR COMPLEXES
US20040241703A1 (en) * 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7939059B2 (en) * 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
EA009607B1 (en) 2003-05-21 2008-02-28 Арес Трейдинг С.А. Tnf-like secreted protein
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
PE20060817A1 (en) * 2004-09-10 2006-10-10 Wyeth Corp HUMANIZED AND CONJUGATED ANTI-5T4 ANTIBODIES ANTI-5T4 / CALICHEAMICIN ANTIBODIES
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
PL2064325T3 (en) 2006-09-01 2012-05-31 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US7744890B2 (en) * 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
CN107252489A (en) 2009-04-13 2017-10-17 法国健康和医学研究院 HPV particles and application thereof
JP5908401B2 (en) * 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Blood coagulation protein complex
CN102573920B (en) 2009-07-27 2015-01-14 利普森技术有限公司 Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2459224T3 (en) 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
CN103269723B (en) 2010-12-22 2017-04-05 百深有限责任公司 For couple water soluble derivative of fatty acid and the material and method of protein
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
US9265969B2 (en) * 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
ES2724232T3 (en) 2012-01-24 2019-09-09 Pfizer 5T4 positive circulating tumor cell detection procedures and 5T4 positive cancer diagnostic procedures in a mammalian subject
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
PT3046583T (en) 2013-09-18 2019-05-30 Aura Biosciences Inc Virus-like particle conjugates for treatment of tumors
JP6718444B2 (en) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
EP4219544A1 (en) 2015-03-10 2023-08-02 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2017024000A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
MX2018005468A (en) 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Targeted cancer therapy.
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US10066023B2 (en) 2015-10-30 2018-09-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
BR112019017628A2 (en) 2017-02-24 2020-07-07 Macrogenics, Inc. cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN108148905A (en) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) One section can be as the sequence of depression marker
EA202092122A1 (en) 2018-03-08 2020-12-03 Фейнз Терапьютикс, Инк. ANTIBODIES AGAINST TIP-1 AND THEIR APPLICATION
EP3765493A2 (en) 2018-03-12 2021-01-20 Genmab A/S Antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
WO1994011513A1 (en) * 1992-11-13 1994-05-26 Medical Research Council Heat shock proteins and the treatment of tumours
WO1996015238A1 (en) * 1994-11-16 1996-05-23 Bradley Michael John Stringer Targeted t lymphocytes
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO1996030512A1 (en) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Conditional expression system
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
CA2016897A1 (en) 1989-05-17 1990-11-17 John W. Wills Retrovirus-mediated secretion of recombinant products
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5582826A (en) 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5439654A (en) 1994-03-10 1995-08-08 Steris Corporation Cutter for opening sterilant reagent cups
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
WO1997017090A1 (en) * 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
WO1997017457A2 (en) 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
SE9601245D0 (en) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
ES2332435T3 (en) 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited VECTOR DIRECTED TO TUMORS.
DE19724502C1 (en) 1997-06-11 1998-10-08 Webasto Thermosysteme Gmbh Auxiliary heating device for motor vehicle
DE69934694T2 (en) 1998-08-10 2007-10-04 Agensys, Inc., Santa Monica BPC-1: A DISEASED BRAIN SPECIFIC PROTEIN EXPRESSED AND EMBROIDERED BY PROSTATE AND BLADDER CANCER CELLS
JP2003515323A (en) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド Body
ATE411342T1 (en) 1999-11-18 2008-10-15 Oxford Biomedica Ltd SCFV ANTIBODIES AGAINST DISEASE-ASSOCIATED MOLECULES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
WO1994011513A1 (en) * 1992-11-13 1994-05-26 Medical Research Council Heat shock proteins and the treatment of tumours
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO1996015238A1 (en) * 1994-11-16 1996-05-23 Bradley Michael John Stringer Targeted t lymphocytes
WO1996030512A1 (en) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Conditional expression system
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAMBERLAIN R.S. ET AL.: "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines", CANCER RESEARCH., vol. 56, no. 12, 15 June 1996 (1996-06-15), MD US, pages 2832 - 2836, XP002083197 *

Also Published As

Publication number Publication date
US20050032216A1 (en) 2005-02-10
IL132596A0 (en) 2001-03-19
EP1012259B1 (en) 2009-09-30
DK1012259T3 (en) 2010-01-18
US7531648B2 (en) 2009-05-12
US7718627B2 (en) 2010-05-18
ES2332435T3 (en) 2010-02-04
EP1012259A2 (en) 2000-06-28
US20030018004A1 (en) 2003-01-23
AU7780198A (en) 1998-12-21
CY1109686T1 (en) 2014-08-13
ATE444358T1 (en) 2009-10-15
US20090017532A1 (en) 2009-01-15
CN1224712C (en) 2005-10-26
NO995901D0 (en) 1999-12-02
US8084249B2 (en) 2011-12-27
NZ500633A (en) 2002-10-25
US20110065173A1 (en) 2011-03-17
US20060286634A1 (en) 2006-12-21
AU747602B2 (en) 2002-05-16
EP1717248A1 (en) 2006-11-02
DE69841204D1 (en) 2009-11-12
NO995901L (en) 2000-02-04
US6852703B1 (en) 2005-02-08
PT1012259E (en) 2009-11-06
JP2009153524A (en) 2009-07-16
CA2292760A1 (en) 1998-12-10
JP2002507117A (en) 2002-03-05
CN1258319A (en) 2000-06-28
JP2011000122A (en) 2011-01-06
WO1998055607A2 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
WO1998055607A3 (en) Tumor targeted vector
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
PL309403A1 (en) Modified cutinases, dna, vector and host
IL109092A (en) Tumor suppressor gene, protein expressed thereby, vectors containing said gene, and use of said vector and protein in cancer treatment
IL110284A0 (en) Viral vectors and their use in gene therapy
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
NZ237198A (en) Zymogen form of protein c, dna, vector and use as a pharmaceutical
GR3036979T3 (en) Coupling product obtained from hystamine and an amino acid.
GB9323429D0 (en) Therapy
HU9501771D0 (en) Modified cutinases, dna, vector and host
AU1384995A (en) Human circulating cytokine cc-1
AU5847194A (en) Novel entomopoxvirus genes, proteins and methods of use thereof
AU3574900A (en) Human cervical cancer 1 protooncogene and protein encoded therein
CA2117795A1 (en) Gustducin Materials and Methods
EP0666313A3 (en) Targeting of telomerase in cancer gene therapy.
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
EP1431391A3 (en) Rantes mutants and therapeutic applications thereof
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
WO2001014415A3 (en) Egfh2 genes and gene products
GB9710636D0 (en) Novel mixture
WO1998050397A3 (en) Chimeric oligonucleotides and the use thereof
AU3928193A (en) Plasmilar gene, peptide and methods of use
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same
Chiyotani Stone Flakes, Human Beings and Clinical Medicine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132596

Country of ref document: IL

Ref document number: 98805529.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 500633

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 77801/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2292760

Country of ref document: CA

Ref document number: 2292760

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997011207

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998925827

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09445375

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998925827

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997011207

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 77801/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1019997011207

Country of ref document: KR